Table 3. Demographic and clinical characteristics of patients enrolled into the pilot study.

Characteristic	Pre-ART (n = 641)	ART (n = 435)	Total (n = 1,076)
Female	433 (67.7%)	276 (63.4%)	710 (66.0)
Age (y)	37 (30–44)	39 (33–46)	38 (31–45)
WHO clinical stage
Stage I	462 (72.4%)	103 (23.7%)	565 (52.7%)
Stage II	127 (19.9%)	171 (39.3%)	298 (27.8%)
Stage III	47 (7.4%)	152 (34.9%)	199 (18.5%)
Stage IV	2 (0.3%)	9 (2.1%)	11 (1.0%)
Baseline weight (kg)	54 (49–59)	52 (46–58)	53 (46–58)
Baseline CD4 count (cells/µl)	643 (464–846)	184 (116-–231)	382 (194–694)
Time since enrolment (mo)	4.1 (0.6–11.7)	14.4 (7.7–22.2)	8.0 (1.7–16.7)
Time on ART (mo)	—	8.3 (2.6–15.9)	—

Data reported as either frequency (percent) or as median (IQR).